Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials

Rotigotine—a non-ergot dopamine agonist—has two advantages; it can stimulate all dopamine receptors (D1–D5) like innate dopamine, and its transdermal administration provides continuous dopaminergic stimulation. The age of the patient impacts the effect and adverse events of anti-parkinsonian treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomoto, Masahiro, Iwaki, Hirotaka, Kondo, Hiroyuki, Sakurai, Masaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808069/
https://www.ncbi.nlm.nih.gov/pubmed/29164312
http://dx.doi.org/10.1007/s00415-017-8671-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808069/
https://www.ncbi.nlm.nih.gov/pubmed/29164312
http://dx.doi.org/10.1007/s00415-017-8671-0

Ejemplares similares